In a deal to sell the 50% ownership stake, Biogen would receive up to $2.3 billion.
In 2012, Biogen invested a 15% stake in Samsung Bioepis and then increased ownership up to 50% less 1 share in June 2018. However, it’s now extracting itself from the biosimlar joint venture with Samsung Biologics.
Biogen is selling its stake for up to $2.3 billion.
“We are thankful to Samsung Biologics for a productive collaboration since 2012,” Michel Vounatsos, CEO at Biogen, said in a statement. “We believe biosimilars are essential to help sustain healthcare systems and represent an important value creation opportunity for Biogen.”
Under the agreement, Biogen will receive $1 billion in cash at closing, $812.5 million at the first anniversary of the transaction close, and $437.5 million at the second anniversary of the transaction close. Biogen is also eligible to receive up to $50 million upon achievement of certain commercial milestones.
“The full buyout of Biogen’s stake is expected to accelerate Samsung Bioepis’ biosimilar development capabilities and future performance in novel drug development, with improved autonomy and agility in business operations,” according to a press release from Samsung Biologics.
Samsung Bioepis’ Approved Drugs
In April 2019, FDA approved Eticovo, an etancercept biosimilar. At the time, the biosimilar had already been approved in a variety of other markets under the names Benepali and Brenzys.
The FDA approval was for all indications of the reference drug, Enbrel: rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis, psoriatic arthritis (PsA), plaque psoriasis, and ankylosing spondylitis (AS).
Eticovo was the second etanercept biosimilar approved after Sandoz’s Erelzi; however, neither have launched in the United States yet.
Renflexis, an infliximab biosimilar to Remicade, was approved in April 2017. The tumor necrosis factor blocker was approved for multiple indications: adult and pediatric Crohn’s disease, ulcerative colitis (UC), RA, AS, PsA, and plaque psoriasis.
It was the second infliximab biosimilar approved after Inflectra from Celltrion/Pfizer. Since then, 2 others have been approved: Avsola and Ixifi. However, Ixifi will not be marketed in the United States since it is also from Pfizer and the company decided to avoid competing with Inflectra.
An adalimumab biosimilar (Hadlima) has been approved since July 2019, although it will not launch until June 2023 as a result of a settlement with AbbVie, the maker of the originator product, Humira. Hadlima is approved for RA, juvenile idiopathic arthritis, PsA, AS, Crohn disease, UC, and plaque psoriasis.
There are a total of 7 adalimumab biosimilars approved in the United States and Amjevita, the first approved in September 2016, will be the first to market with an anticipated launch of January 2023. Cytelzo was approved August 2017 and has an anticipated launch of July 1, 2023, but it has the added advantage of already being approved as an interchangeable biosimilar.
A trastuzumab biosimilar, Ontruzant, was approved in January 2019 to treat HER2-positive breast cancer and HER2 overexpressing gastric cancer, and it launched in the United States in April 2020. Another 4 trastuzumab biosimilars (reference, Herceptin) are approved and have launched.
Finally, the company has a ranibizumab biosimilar (Byooviz), which was approved September 2021. This is the first ranibizumab biosimilar of reference Lucentis, and it is the first ophthalmology biosimilar to gain approval. It is approved to treat neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion, and myopic choroidal neovascularization.
Byooviz will not launch until June 2022 due to a licensing agreement between Samsung Bioepis and Biogen and the originator company, Genentech.
Outside of the United States, Samsung Bioepis has a bevacizumab biosimilar, which is sold as Aybintio in Canada and the European Union and as Onbevzi in the European Union and the Republic of Korea.
In the Pipeline
In addition to the approved biosimilars, Samsung Bioepis has 5 additional products in the pipeline.
SB12 is an eculizumab biosimilar based on Soliris, an immunosuppressive drug that treats paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. SB12 is currently in a phase 3, randomized, double-blind, multicenter, cross-over study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB12 and Soliris (NCT04058158).
The company also has a second ophthalmology candidate with SB15, an aflibercept biosimilar based on the reference product Eylea. This is also in phase 3 with a randomized, double-masked, parallel group, multicenter study to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of SB15 vs Eylea in patients with neovascular AMD (NCT04450329).
SB16 is a denosumab biosimilar to reference product Prolia in a phase 3, randomized, double-blind, multicenter study evaluating the safety, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of the biosimilar compared with Prolia in postmenopausal women with osteoporosis (NCT04664959).
Finally, SB17 is a ustekinumab biosimilar candidate to reference product Stelara. It is in a phase 3, randomized, double-blind, multicenter study to evaluate the safety, efficacy, tolerability, pharmacokinetics, and immunogenicity of the biosimilar compared with Stelara in patients with moderate to severe plaque psoriasis.
In addition to the biosimilars in the pipeline, Samsung Bioepis also has SB26, a novel biologic. It is an ulinastatin-Fc fusion protein that is intended to treat severe acute pancreatitis, and it is in a phase 1 trial.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Public Payer in Poland Saves €243 Million by Using Biosimilar TNF Inhibitors
November 11th 2023The use of biosimilars of tumor necrosis factor (TNF) inhibitors within Poland’s public payer saved over €243 million from 2013 to 2021, with about 68% of that coming from the rheumatic musculoskeletal diseases alone.
Real-World Data Confirm Safety, Efficacy of CT-P13 in Inflammatory Diseases
November 9th 2023A real-world analysis from Japan confirmed that CT-P13, an intravenous infliximab biosimilar, had comparable safety and efficacy to the reference product (Remicade; infliximab) in patients with immune-mediated inflammatory diseases.